Literature DB >> 11212235

Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect.

X Huang1, M K Wong, Q Zhao, Z Zhu, K Z Wang, N Huang, C Ye, E Gorelik, M Li.   

Abstract

Endostatin is a potent and specific antiangiogenic protein capable of inhibiting the growth of murine and xenotransplanted human tumors. Thus far, however, recombinant endostatin prepared from Escherichia coli is insoluble after purification and therefore inappropriate for clinical settings. A soluble form of endostatin is available from a yeast system with relatively low yield and high cost, which has made it difficult to produce endostatin in quantities sufficient for extensive clinical evaluation. In this study, we developed a protocol to generate soluble recombinant murine endostatin from E. coli at a yield of 150 mg/liter-culture and 99% purity. The in vivo antiangiogenic and antitumor activities of the soluble recombinant endostatin are equally as potent as those of the previously published insoluble form. A similar protocol may be used to produce soluble human endostatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.

Authors:  Chun-Te Chen; Hirohito Yamaguchi; Hong-Jen Lee; Yi Du; Heng-Huan Lee; Weiya Xia; Wen-Hsuan Yu; Jennifer L Hsu; Chia-Jui Yen; Hui-Lung Sun; Yan Wang; Edward T H Yeh; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2011-05-24       Impact factor: 6.261

2.  Cloning and Expression of Recombinant Human Endostatin in Periplasm of Escherichia coli Expression System.

Authors:  Abbas Mohajeri; Yones Pilehvar-Soltanahmadi; Mohammad Pourhassan-Moghaddam; Jalal Abdolalizadeh; Pouran Karimi; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2016-06-30

3.  Retrovirus-mediated gene transfer of human endostatin inhibits growth of human liver carcinoma cells SMMC7721 in nude mice.

Authors:  Xuan Wang; Fu-Kun Liu; Xi Li; Jie-Shou Li; Gen-Xin Xu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

4.  Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

Authors:  Hongmei Wei; Shukui Qin; Xiaojin Yin; Yali Chen; Haiqing Hua; Lin Wang; Ningrong Yang; Yingxia Chen; Xiufeng Liu
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

Review 5.  Developments in purification methods for obtaining and evaluation of collagen derived endogenous angioinhibitors.

Authors:  Venugopal Gunda; Raj K Verma; Smita C Pawar; Yakkanti A Sudhakar
Journal:  Protein Expr Purif       Date:  2013-11-09       Impact factor: 1.650

6.  MR reporter gene imaging of endostatin expression and therapy.

Authors:  Kai Wang; Kezheng Wang; Baozhong Shen; Tao Huang; Xilin Sun; Weihua Li; Gang Jin; Lin Li; Lihong Bu; Renfei Li; Dan Wang; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2009-12-03       Impact factor: 3.488

7.  Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma.

Authors:  Pei-Yuan Li; Ju-Sheng Lin; Zuo-Hua Feng; Yu-Fei He; He-Jun Zhou; Xin Ma; Xiao-Kun Cai; De-An Tian
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

8.  Molecular cloning, expression and purification of recombinant soluble mouse endostatin as an anti-angiogenic protein in Escherichia coli.

Authors:  Kheirollah Yari; Saboor Afzali; Hadi Mozafari; Kamran Mansouri; Ali Mostafaie
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

Review 9.  Cellular actions and signaling by endostatin.

Authors:  Ramani Ramchandran; S Ananth Karumanchi; Jun-ichi Hanai; Seth L Alper; Vikas P Sukhatme
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2002       Impact factor: 1.807

10.  Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery.

Authors:  Li Li; Jia-Ling Huang; Qi-Cai Liu; Pei-Hong Wu; Ran-Yi Liu; Yi-Xin Zeng; Wen-Lin Huang
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.